Bivalirudin for anticoagulation in mechanical aortic valve replacement and heparin-induced thrombocytopenia

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 4, 2006, Pages 331-333

  Klein, Moti ^a   Tomer, Aaron ^a   Swartz, Andre ^a   Koyffman, Leonid ^a   Weksler, Natan ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Bivalirudin; Heparin induced thrombocytopenia; Thrombosis

Indexed keywords

DANAPAROID; HEPARIN; HIRULOG; WARFARIN;

ADULT; ANTICOAGULATION; AORTA VALVE PROSTHESIS; AORTA VALVE REPLACEMENT; ARTICLE; CASE REPORT; DRUG EFFICACY; DRUG INDICATION; FEMALE; HEALTH CARE AVAILABILITY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; PRIORITY JOURNAL;

EID: 33646806828     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000224857.73119.97     Document Type: Article

References (22)

1. Alberio L, Kimmerle S, Baumann A, Taleghani BM, Biasiutti FD, Lammle B. Rapid determination of anti-heparin/platelet factor 4 antibody titers in the diagnosis of heparin-induced thrombocytopenia. Am J Med 2003; 114:609-610.
2. Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br J Haematol 1997; 98:648-656.
3. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56:12-16.
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:311S-337S.
5. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655.
6. Kodityal S, Manhas AH, Udden M, Rice L. Danaparoid for heparin-induced thrombocytopenia: an analysis of treatment failures. Eur J Haematol 2003; 71:109-113.
7. Cochran K, DeMartini TJ, Lewis BE, O'Brien J, Steen LH, Grassman ED, et al. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia. J Invasive Cardiol 2003; 15:617-621.
8. Farner B, Eichler P, Kroll H, Greinacher. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85:950-957.
9. Greinacher A, Janssens U, Berg G, Markus B, Kwasny H, Kemkes-Matthes B, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation 1999; 100:587-593.
10. Greinacher A, Volpel H, Janssens U, Hach-Wunderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99:73-80.
11. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003; 110:73-82.
12. Warkentin TE. Bivalent direct thrombin inhibitors: hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17:105-125.
13. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001; 142:952-959.
14. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333:764-769.
15. Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, et al. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 2003; 15:611-616.
16. Davis Z, Anderson R, Short D, Garber D, Valgiusti A. Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass. Ann Thorac Surg 2003; 75:264-265.
17. Merry AF, Raudkivi PJ, Middleton NG, McDougall JM, Nand P, Mills BP, et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004; 77:925-931.
18. Chamberlin JR, Lewis B, Leya F, Wallis D, Messmore H, Hoppensteadt D, et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using Hirulog. Can J Cardiol 1995; 11:511-514.
19. Rice L. Evolving management strategies for heparin-induced thrombocytopenia [abstract]. Semin Hematol 2005; 41 (Suppl 3):S15.
20. Berilgen JE, Nguyen PH, Baker KR, Rice L. Bivalirudin treatment of heparin-induced thrombocytopenia [abstract]. Blood 2003; 102:537a.
21. Francis J, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, in the treatment of heparin-induced thrombocytopenia [abstract]. J Thromb Haemost 2003; 1 (Suppl 1):P1909.
22. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther 2002; 71:433-439.